TG Therapeutics is a biotechnology business based in the US. TG Therapeutics shares (TGTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $22.83 – a decrease of 2.23% over the previous week. TG Therapeutics employs 300 staff and has a trailing 12-month revenue of around $346.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $22.83 |
|---|---|
| 52-week range | $6.46 - $26.41 |
| 50-day moving average | $22.21 |
| 200-day moving average | $17.89 |
| Wall St. target price | $34.29 |
| PE ratio | 35.0441 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.68 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $22.83 from 2024-10-01
| 1 week (2024-09-25) | -2.23% |
|---|---|
| 1 month (2024-08-30) | -2.81% |
| 3 months (2024-07-02) | 24.69% |
| 6 months (2024-04-02) | 58.10% |
| 1 year (2023-10-02) | 179.78% |
|---|---|
| 2 years (2022-09-30) | 285.64% |
| 3 years (2021-10-01) | 33.71 |
| 5 years (2019-10-02) | 342.87% |
Valuing TG Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of TG Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
TG Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, TG Therapeutics shares trade at around 35x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
TG Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $102 million.
The EBITDA is a measure of a TG Therapeutics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $346.7 million |
|---|---|
| Operating margin TTM | 12% |
| Gross profit TTM | $2.5 million |
| Return on assets TTM | 20.47% |
| Return on equity TTM | 87.78% |
| Profit margin | 27.6% |
| Book value | $1.24 |
| Market Capitalization | $3.7 billion |
TTM: trailing 12 months
We're not expecting TG Therapeutics to pay a dividend over the next 12 months.
TG Therapeutics's shares were split on a 100:5625 basis on 29 April 2012. So if you had owned 5625 shares the day before before the split, the next day you'd have owned 100 shares. This wouldn't directly have changed the overall worth of your TG Therapeutics shares – just the quantity. However, indirectly, the new 5525% higher share price could have impacted the market appetite for TG Therapeutics shares which in turn could have impacted TG Therapeutics's share price.
Over the last 12 months, TG Therapeutics's shares have ranged in value from as little as $6.46 up to $26.41. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TG Therapeutics's is 2.212. This would suggest that TG Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
TG Therapeutics, Inc. , a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S. A.
Step 1: Open and fund your account, Step 2: Enable options trading, Step 3: Select and trade options, Step 4: Closing options trades.
Learn the basics of put options: what they are, how they work and a few examples.
Learn the basics of call options: what they are, how they work and examples.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
Check out the best-performing ETFs so far in 2024.
What to expect when you sign up for a Zacks Trade brokerage account.